Exploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery

Exosomes are cell‐derived nanovesicles that transfer molecular cargo to recipient cells and mediate intercellular communication. Momentous progress in elucidating the biological capabilities and functionalities of exosomes has created new possibilities in their applications for diagnosis and therapy. This review covers the state‐of‐art understanding of circulating exosomes as cancer biomarkers, as well as the development of exosome‐based drug delivery platforms.

Abstract

Exosomes are cell‐derived nanovesicles that transfer molecular cargo from donor to recipient cells and mediate intercellular communication. Advancement in elucidating the biological capabilities and functionalities of exosomes has revealed the striking roles of exosomes as conveyors of bioactive molecules across the biological barriers. Tumor‐derived exosomes hold great promise to serve as a liquid biopsy tool for cancer diagnosis and prognosis, as large quantities of exosomes are excreted by tumor cells continuously into the circulation, carrying the molecular cargo (DNA, RNA, proteins) reflective of the genetic and signaling alterations in tumor cells. Two inherent characteristics of exosomes offer important opportunities for drug delivery: their superb transcellular permeability and biocompatibility. Exosomes are uniquely capable of encapsulating a variety of payloads and deliver them to the target tissues. This review discusses the potential of tumor‐derived exosomes in cancer liquid biopsies as well as the underlying mechanisms. Furthermore, the recent progress of developing exosomes as highly versatile and efficient drug carriers is also summarized.

http://bit.ly/2CAEFGQ